Systemic Retinoid Therapy: A Status Report on Optimal Use and Safety of Long-Term Therapy

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 185-193

  Desai, Alpesh ^a,b   Kartono, Francisca ^b   Del Rosso, James Q ^c  

^a Heights Dermatology   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTIBIOTIC AGENT; CYCLOSPORIN; ERYTHROMYCIN; ETRETIN; ETRETINATE; ISOTRETINOIN; METHOTREXATE; PSORALEN; RETINOIC ACID; RETINOID; TETRACYCLINE;

ACNE; ACNE VULGARIS; ALOPECIA; ARTHRALGIA; AUTOMUTILATION; BACKACHE; BIRTH DEFECT; BONE DISEASE; BONE MALFORMATION; BRAIN PSEUDOTUMOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MALFORMATION; CHEILITIS; COMBINATION CHEMOTHERAPY; DARIER DISEASE; DEPRESSION; DESQUAMATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; ECZEMA; EPIPHYSIS DISEASE; EPISTAXIS; EXTERNAL EAR MALFORMATION; EYE MALFORMATION; FACE DYSMORPHIA; GENODERMATOSIS; GRANULATION TISSUE; HAIR DISEASE; HAIR THINNING; HEADACHE; HUMAN; HYPERLIPIDEMIA; INTRACRANIAL HYPERTENSION; KERATODERMA; KERATOSIS PALMOPLANTARIS; LAMELLAR ICHTHYOSIS; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MUCOSAL DRYNESS; MYALGIA; NAIL DISEASE; NAUSEA; NERVOUS SYSTEM MALFORMATION; OSTEOPOROSIS; PALMAR DESQUAMATION; PAPILLEDEMA; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; PLANTAR DESQUAMATION; PREMATURE EPIPHYSEAL CLOSURE; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN CANCER; SKIN FRAGILITY; SKIN INFECTION; THYMUS DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL DISORDER; VOMITING; XERODERMA;

DRUG DESIGN; HUMANS; RETINOIDS; SKIN DISEASES;

EID: 34047264859     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.02.002     Document Type: Review

References (67)

1. Wolbach S., and Howe P. Tissue changes following deprivation of fat-soluble A-vitamin. J Exp Med 42 (1925) 753-778
2. Giudice G., and Fuchs E. Vitamin A-mediated regulation of keratinocyte differentiation. Methods Enzymol 190 (1990) 18-29
3. Brecher A., and Orlow S. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 49 (2003) 171-182
4. Gollnick H., and Dummler U. Retinoids. Clin Dermatol 15 (1997) 799-810
5. Peck G., Yoder F., Strauss J., et al. Prolonged remissions of cystic and conglobata acne with 13-cis-retinoic acid. N Engl J Med 300 (1979) 329-333
6. Dockx P., Decree J., and Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 133 (1995) 426-432
7. Vandeghinste N., De Bersaques J., Geerts M., et al. Acitretin as cancer chemoprophylaxis in a renal transplant recipient. Dermatology 185 (1992) 307-308
8. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind placebo controlled study. J Clin Oncol 1995;13:1933-1938.
9. McNamara I., Muir J., and Galbraith A. Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 21 (2002) 1201-1205
10. George R., Weightman W., Russ G.R., et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 43 (2002) 269-273
11. Chambon P. The retinoid signaling pathway: molecular and genetic analysis. Semin Cell Biol 5 (1994) 115-125
12. Saurat K. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 41 (1999) S2-S6
13. Lee C., and Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 6 10 (2005) 1725-1734
14. Fisher G., Talwar H., Xiao J., et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor protein in human skin. J Biol Chem 269 (1994) 20629-20635
15. Xiao J., Durand B., Chambon P., et al. Endogenous retinoic acid receptor (RAR)-retinoid X receptor (RXR) heterodimers are the major functional forms in adult human keratinocytes. J Biol Chem 270 (1995) 2001-2011
16. Griffiths C., Dabelsteen E., and Voorhees J. Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. Br J Dermatol 134 (1996) 431-436
17. Orfanos C., Zouboulis C., Almond-Roesler B., et al. Current use and future potential role of retinoids in dermatology. Drugs 53 3 (1997) 358-388
18. Zouboulis C., Korge B., Akamatsu H., et al. Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J Invest Dermatol 96 (1991) 792-797
19. Kempf W., Kettelhack N., Duvic M., et al. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17 (2003) 1405-1419
20. Struy H., Bohne M., Morenz J., et al. Effects of retinoids on human neutrophil derived free radicals. Eur J Haematol 59 Suppl 57 (1996) 52
21. Dupuy P., Bagot M., Heslan M., et al. Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. J Invest Dermatol 93 (1989) 455-459
22. Chalmers R. Retinoid therapy-a real hazard for the developing embryo. Br J Obstet Gynaecol 99 (1992) 276-278
23. DiGiovanna J., Zech L., Ruddel M., et al. Etretinate. Persistent serum levels after long-term therapy. Arch Dermatol 125 (1989) 246-251
24. Jones D. A comparison of 13-cis-retinoic acid and erythromycin treatment in severe acne. Br J Dermatol 109 Suppl 24 (1983) 27-28
25. Langner A., Wolska H., Fraczykowska M., et al. 13-cis-retinoic acid and tetracycline versus 13-cis-retinoic acid alone in the treatment of nodulocystic acne. Dermatologica 170 4 (1985) 185-188
26. Wessels F., Anderson A.N., and Kropman K. The cost-effectiveness of isotretinoin in the treatment of acne. Part I. A meta-analysis of effectiveness literature. S Afr Med J 89 7 Pt 2 (1999) 780-784
27. Chivot M., and Midoun H. Isotretinoin and acne-a study of relapses. Dermatologica 180 4 (1990) 240-243
28. Charakida A., Mouser P.E., and Chu A.C. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin Drug Saf 3 2 (2004) 119-129
29. Lebwohl M., and Kathryn M. New roles for systemic retinoids. J Drugs Dermatol 5 5 (2006) 406-409
30. Saurat J., Geiger J., Amblard P., et al. Randomized double-blind multi-center study comparing acitretin-PUVA, etretinate-PUVA, and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 177 (1988) 218-224
31. Iest J., and Boer J. Combined treatment of psoriasis with acitretin alone and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 120 (1989) 665-670
32. Ruzicka T., Sommerburg C., Braun-Falco O., et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 126 (1990) 482-486
33. Green C., Lakshmipathi T., Johnson B., et al. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 127 (1992) 5-9
34. Stebbins W., and Lebwohl M. Biologics in combination with nonbiologics: efficacy and safety. Dermatol Ther 17 (2004) 432-440
35. Pearce D., Klinger S., Ziel K., et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol 142 (2006) 1000-1004
36. Ruiz-Maldonado R., and Tamayo L. Retinoids in disorders of keratinization: their use in children. Dermatologica 175 (1987) 123-132
37. Tamayo L., Ruiz-Maldonado R., et al. Long-term follow-up of 30 children under oral retinoid Ro 10-9359. In: Orfanos C.E., Braun-Falco O., and Farber E.M. (Eds). Retinoids: advances in basic research and therapy (1981), Springer-Verlag, Berlin 287-294
38. Blanchet-Bardon C., Nazarro V., Rognin C., et al. Acitretin in the treatment of severe disorders of keratinization. J Am Acad Dermatol 24 (1991) 982-986
39. Bollag W., and Holdener E. Retinoids in cancer prevention and therapy. Ann Oncol 3 7 (1992) 513-526
40. Peck G. Long-term retinoid therapy is needed for maintenance of cancer chemopreventive effect. Dermatologica 175 Suppl 1 (1987) 138-144
41. Euvrard S., Kanitakis J., and Claudy A. Skin cancers after organ transplantation. N Engl J Med 348 (2003) 1681-1691
42. Chen K., Craig J., and Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 152 (2005) 518-523
43. Mc Kenna D., and Murphy G. Skin cancer chemprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 140 (1999) 656-660
44. De Sevaux R., Smit J., De Jong E., et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 49 (2003) 407-412
45. Kovach B., Sams H., and Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 19 6 (2005) 726-734
46. Harwood C., Leedham-Green M., Leigh I., et al. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients. Arch Dermatol 141 (2005) 456-464
47. Stasko T., Brown M., Carucci J., et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 30 (2004) 642-650
48. Van de Kerkhof P., and de Rooij M.J. Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporine treatment: response to long-term acitretin maintenance. Br J Dermatol 136 (1997) 275-278
49. Yerebakan O., Ermis O., Yilmaz E., et al. Treatment of arsenical keratosis and Bowen's disease with acitretin. Int J Dermatol 41 2 (2002) 84-87
50. Lebwohl M., Tannis C., and Carrasco D. Acitretin suppression of squamous cell carcinoma: a case report and literature review. J Dermatol Treat 14 Suppl 2 (2003) 3-6
51. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 27 (1992) S29-S33
52. Ellis C., and Krach K. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45 Suppl (2001) S150-S157
53. Jones M., Pais M., and Omiya B. Bony overgrowths and abnormal calcifications about the spine. Radiol Clin North Am 26 (1988) 1213-1234
54. Peck G., DiGiovanna J., et al. The retinoids. In: Freedberg I., and Eisen A. (Eds). Dermatology in general medicine (1999), McGraw-Hill, New York 2810-2820
55. Heudes A., and Laroche L. Muscular damage during isotretinoin treatment. Ann Dermatol Venereol 125 (1998) 94-97
56. Landau M., Mesterman R., Ophir J., et al. Clinical significance of markedly elevated creatinine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 81 (2001) 350-352
57. US Food and Drug Administration. Isotretinoin (marketed as Accutane) capsule information. October 2006. Available at: http://www.fda.gov/cder/drug/infopage/accutane/default.htm. Accessed June 11, 2006.
58. Exner J., Dahod S., and Pochi P. Pyogenic granuloma-like acne lesions during isotretinoin therapy. Arch Dermatol 119 (1983) 808-811
59. Bigby M., and Stern R. Adverse reactions to isotretinoin: a report from the adverse drug reaction reporting system. J Am Acad Dermatol 18 (1988) 543-552
60. Goulden V., Laytom A., and Cunliffe W. Long-term safety of isotretinoin as a treatment for acne vulgaris. Br J Dermatol 131 (1994) 360-363
61. Nguyen E., and Wolverton S. Systemic retinoids. In: Wolverton S., and Wilkin J. (Eds). Systemic drugs for skin diseases (2000), WB Saunders, Philadelphia 269-310
62. Weinberg J. iPLEDGE allegiance. Cutis 76 6 (2005) 356
63. Stuart B., and Litt I. Tetracycline-associated intracranial hypertension in an adolescent: a complication of systemic acne therapy. J Pediatr 92 (1978) 679-680
64. Soriatane, inventor. Connetics Corporation, assignee [Package insert]. Palo Alto (CA); 2003.
65. Bleiker T., Bourke J., Graham-Brown R., et al. Etretinate may work where acitretin fails. Br J Dermatol 136 3 (1997) 368-370
66. Bremner J., Fani N., Ashraf A., et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 162 5 (2005) 983-991
67. Starling III J., and Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 4 6 (2005) 690-696